Maximilian Mair is a clinician-scientist at the Division of Oncology at the Medical University of Vienna, Austria. His research activities focus on clinical and translational neuro-oncology, with particular interests in precision oncology, molecular imaging and theranostics in gliomas and meningiomas. He serves as Deputy Head of the Austrian Clinical Research Group ATTRACT, a nationwide precision oncology initiative for glioblastoma, and is actively involved in several neuro-oncology networks including EANO, the EORTC Brain Tumor Group, and RANO. He serves as chair of the EANO Youngsters Committee in 2026-2028. 

George Petrescu, MD, PhD, is a neurosurgeon and lecturer at Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. His research interests include finding new therapeutic targets for primary brain tumors and improving the quality of life of neuro-oncological patients following surgical resection. He is also involved in developing educational applications using modern techniques such as extended reality for teaching medical students and residents interested in the field of neuro-oncology, as well as for informing patients.

Franziska Maria Ippen, MD, is a neurology fellow and clinician-scientist at the Department of Neurology at Heidelberg University Hospital, Germany, where she leads a specialized outpatient clinic for patients with brain metastases and leptomeningeal disease. Her translational research focuses on brain metastases, tumor evolution and the brain tumor microenvironment, using single-cell and spatial multi-omics approaches at the Department of Neuropathology in Heidelberg. Previously, she was a postdoctoral research fellow at Massachusetts General Hospital and Harvard Medical School, focusing on targeted therapies for brain metastases. Her broader interests include clinical trials and the development of novel biomarkers and therapeutic strategies for patients with primary and metastatic CNS tumors.

Felix Ehret, MD, is a radiation oncology resident and assistant professor in the Department of Radiation Oncology at Charité, Berlin, Germany. He is also a current research fellow at Massachusetts General Hospital and Harvard Medical School. His research interests focus on refining radiotherapy for meningiomas and gliomas. Additionally, he investigates the use of stereotactic radiosurgery and stereotactic body radiotherapy, encompassing both clinical and translational projects.

Antonio C. Fuentes-Fayos, PhD, is a neuro-oncology researcher and lecturer at the University of Córdoba and the Maimonides Biomedical Research Institute of Córdoba (IMIBIC), Spain. His research focuses on the immunopeptidome of adult and pediatric brain tumors, combining molecular analyses, single-cell sequencing, peptidomics, and preclinical modeling. He aims to characterize the interplay between glioma heterogeneity, immune response, and tumor evolution in order to improve the efficacy of current therapies.

Maximilian Mastall, MD, PhD, is a neurology resident at the University Hospital Zurich, Switzerland. He obtained his MD focusing on immune cell infiltration into glioblastoma at the Neurosurgical Department of the University Hospital Heidelberg, and his PhD in Cancer Biology at the University of Zurich, generating Chimeric Antigen Receptor (CAR) T cells against glioblastoma. His research interests are novel immunotherapeutic strategies for patients with malignant brain tumors.

Dasha Fedorushkova, MD, is a physician-scientist and PhD candidate at the Netherlands Cancer Institute in Amsterdam, the Netherlands. Her research focuses on translational neuro-oncology, bridging clinical and preclinical approaches to develop novel treatment strategies for brain tumors, with a particular interest in radiosensitization of glioblastoma and drug transport at the blood–brain tumor barrier in brain metastases.

Nico Teske, MD, MSc, is a board-certified neurosurgeon and clinician scientist at University Hospital Erlangen, Germany. He holds an MSc in Clinical Trials from the London School of Hygiene & Tropical Medicine. His research focuses on extent of resection and volumetric imaging in gliomas and meningiomas. He is an active member of the RANO resect group and collaborates with international consortia such as IRRF and ICOM. In parallel, his preclinical translational work focuses on CAR T-cell therapy in medulloblastoma.

Angelo Dipasquale, MD, is a Medical Oncologist at IRCCS Humanitas Research Hospital in Milan (italy), with a main focus on neuro-oncology and early drug development. He completed his residency in Medical Oncology at Humanitas University in Milan, with also a laboratory experience in Erasmus MC (Rotterdam, The NL). He is actively involved in clinical trials involving patients with solid tumors, with a particular interest for adult-type gliomas. His main research interests include IDH mutant gliomas, microenvironment of brain metastasis, early drug development and toxicities from novel anticancer agents.

Anna Lipatnikova, MD, PhD candidate, is completing her postgraduate medical training at Halmstad Hospital, Sweden, while simultaneously pursuing her PhD at the University of Gothenburg. Her PhD project focuses on prognostic markers in lower-grade gliomas. More recently, her research interests have expanded to glioblastoma, with a particular focus on surgical strategies and postoperative outcomes.

Giuseppe Pinto, MD, is a PhD candidate in translational pediatric neuropathology at Heidelberg University Hospital and the German Cancer Research Center (DKFZ) in Heidelberg, Germany. His research focuses on the molecular and multi-omic characterization of pediatric and adolescent and young adult (AYA) central nervous system tumors, with particular interests in rare tumors and the tumor microenvironment. Through his work, he aims to uncover the biological features that define these tumors and translate molecular insights into more precise diagnoses and improved patient-centered therapeutic approaches.

Amber Elyse Corrigan is a Neurology Academic Clinical Fellow at King’s College London. She graduated from King’s with an intercalated degree in Neuroscience and subsequently worked at the National Hospital for Neurology and Neurosurgery before starting her academic clinical fellowship. Her research interests include cerebrovascular complications of brain tumours, neurological treatment toxicity, and artificial intelligence in neuro-oncology. 

Arpi Asminian, MD, is a neurology resident based in Yerevan, Armenia, with a strong interest in neuro-oncology, clinical research, clinical trials, and health equity. Alongside her clinical training, she serves as Global Community Lead at OncoDaily, where she leads international community engagement initiatives, fosters collaboration among oncology professionals, and promotes scientific exchange across borders. She has contributed to research on CNS tumors and neurological disorders.She is passionate about advancing neuro-oncology education, promoting scientific knowledge exchange, and creating opportunities for collaboration among professionals worldwide.

Jolijn Boer, RPh, PhD, is a pharmacist by training and works in Neurology Medical Affairs in the pharmaceutical industry in Berlin, Germany. As the daughter of a glioblastoma patient, she is also engaged as a patient and caregiver representative in the field of brain tumours. She is a member of the EANO Brain Tumour Advocacy Committee (BTAC) and involved in the campaign "Gemeinsam gegen Glioblastom" (Together against Glioblastoma) and the organization "Deutsches Innovationsbündnis Krebs & Gehirn" (German Innovation Alliance for Cancer & Brain).

Marie-Therese Gubi, BSc., is a Medical Student in her final year and works as a Research Assistant in the field of Pediatric Neurooncology at the Medical University of Vienna, Austria. With her personal lived experience, she is engaged as a Patient Expert in national and international projects, with a particular focus on Long-Term Follow-Up Care and Transition. Marie is a member of the EANO Brain Tumor Advocacy Committee (BTAC). She is passionate about bridging the perspectives of patients, healthcare professionals and researchers and fostering meaningful collaboration in neuro-oncology.